UNSPSC 51283727: Cefuzonam sodium

This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6SOU25L22C. European Medicines Agency schedules Cefuzonam sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01141MIG. Cefuzonam sodium generally arises in the molecular formula C16H14N7O5S4.NA. The term 'cefuzonam sodium' is a Japanese Accepted Name designation. Most nations, for tariff and trade purposes, schedule cefuzonam sodium under HS 29419000 and SITC 54139.

As of Q4 2014, CEFUZONAM SODIUM remains US FDA's Preferred Term for this commodity. Cefuzonam sodium bears US NLM identifiers UMLS ID C0124795 and NCI Concept Code C98232. SMILES: CO/N=C(/C1CSC(N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)CSC4CNNS4)C(=O)[O-].[NA+].

UNSPSC 51283727 Cefuzonam sodium is a Commodity code for a specific injectable antibiotic pharmaceutical product, yet the recent state and local opportunities tagged under this code do not reflect procurement of cefuzonam sodium itself. Instead, the tagged records show purchases of entirely different pharmaceutical and medical products — oral antibiotics (doxycycline, ciprofloxacin) and naloxone with drug deactivation systems — suggesting a significant mismatch between the code assignment and the work actually being solicited. State and local buyers do procure pharmaceuticals through cooperative purchasing vehicles and direct awards, but the available records do not support active, relevant procurement activity under this specific commodity code.

The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline and ciprofloxacin tablets under an Invitation for Bid process, while Seminole County, Florida released an IFB in June 2026 for naloxone and drug deactivation systems with quarterly delivery requirements. Both procurements reflect state and local health agencies' reliance on cooperative purchasing frameworks and fixed-term contracts with renewal options, but neither involves cefuzonam sodium or related third-generation cephalosporins. Without evidence of recent, correctly coded opportunities for cefuzonam sodium itself in the state and local market, this code presents limited pursuit opportunity based on current activity data.